Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells

Wang, Li; Shi, Wenyu; Yang, Fan; Tang, Wei; Gapihan, Guillaume; Varna, Mariana; Shen, Zhi-Xiang; Chen, Sai‐Juan; Lebœuf, Christophe; Janin, Anne; Zhao, Wei‐Li

doi:10.3324/haematol.2010.037689

Cited by 15 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zhao et al demonstrated a novel mechanism in which lovastatin inhibits both ligand-induced VEGFR-2 activation through inhibition of receptor internalization and VEGF activation of PI3K/AKT pathway in endothelial cells [72]. Since angiogenesis has a central role in clinically aggressive hematologic malignancies such as nonHodgkin lymphomas [73][74][75], angioimmunoblastic T-cell lymphoma [76,77], ALL [78], AML [79], and multiple myeloma [80], inhibition of the VEGF-mediated intracellular signal via bevacizumab could be further facilitated by blocking the mevalonate pathway.…”

Section: Inhibition Of Angiogenesismentioning

confidence: 99%

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

Bockorny

Dasanu

2014

Ann Hematol

View full text Add to dashboard Cite

Statins have been shown to possess properties that go beyond their lipid-lowering effects. These agents act on the mevalonate pathway and inhibit synthesis of cholesterol, geranylgeranyl pyrophosphate, and farnesyl pyrophosphate, which are necessary for posttranslational modification of the Rho, Rac, and Ras superfamily of proteins. Early phase studies have demonstrated that this modulation of cellular signaling can ultimately exert pro-apoptotic, anti-angiogenic, and immunomodulatory effects, and might even restore chemosensitivity in several hematologic cancers. Nonetheless, these promising preclinical results have not yet migrated from the bench to the bedside as their effectiveness as adjuvant agents in hematologic malignancies is currently uncertain. In the present review, we summarize the existing evidence stemming from preclinical and clinical studies pertaining to the use of statins as adjuvant therapies in hematologic malignancies, and discuss the new insights gained from the ongoing translational research.

show abstract

Section: Inhibition Of Angiogenesismentioning

confidence: 99%

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

Bockorny

Dasanu

2014

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…It is an anti-VEGF monoclonal antibody currently being used in solid tumors and received considerable efficiency [83][84][85]. However, the single-agent therapy of Bevacizumab did not show effective clinical activity for 13 patients with relapsed/refractory CLL in the phase II trials [86].…”

Section: Anti-angiogenic Therapy In Cllmentioning

confidence: 99%

Angiogenic factors in chronic lymphocytic leukemia

Xia¹,

Lu²,

Li³

2012

Leukemia Research

View full text Add to dashboard Cite

“…Moreover, bevacizumab is currently under investigation as a treatment option for newly diagnosed AML in combination with idarubicin and cytarabine [ 145 ]. In vivo and in vitro studies showed that bevacizumab has an ability to enhance the chemotherapeutic effect on T-leukemia/lymphoma cells [ 146 , 147 ]. In the case of HL, bevacizumab caused biological effects, which indicate it is clinically active [ 138 ].…”

Section: Monoclonal Antibodies Used In Clinical Trials or Preclinimentioning

confidence: 99%

Target Therapy in Hematological Malignances: New Monoclonal Antibodies

Podhorecka

Markowicz

Szymczyk

et al. 2014

International Scholarly Research Notices

View full text Add to dashboard Cite

Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor activity. This review provides an overview of the functional characteristics of MoAbs, with some examples of their clinical application. The promising results in the treatment of hematological malignancies have led to the more frequent usage of MoAbs in the therapy. Development of MoAbs is a subject of extensive research. They are a promising method of cancer treatment in the future.

show abstract

Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells

Cited by 15 publications

References 23 publications

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

Angiogenic factors in chronic lymphocytic leukemia

Target Therapy in Hematological Malignances: New Monoclonal Antibodies

Contact Info

Product

Resources

About